Brief: Hillevax Announces Positive Recommendation From Safety Data Monitoring Committee For Mid-stage Trial Of Hil-214 Norovirus Vaccine Candidate
31/08/2022 12:22
Aug 31 (Reuters) - Hillevax Inc HLVX.O :
* HILLEVAX ANNOUNCES POSITIVE RECOMMENDATION FROM SAFETY
DATA
MONITORING COMMITTEE FOR NEST-IN1 PHASE 2B CLINICAL TRIAL OF
HIL-214 NOROVIRUS VACCINE CANDIDATE
* HILLEVAX INC - IMMUNOGENICITY RESULTS FROM FIRST 200
SUBJECTS
EXPECTED IN Q4 2022
* HILLEVAX INC - ENROLLMENT OF REMAINING SUBJECTS IN
NEST-IN1 HAS
RESUMED
Source text for Eikon: ID:nGNXbTxKPG
Further company coverage: HLVX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HilleVax
See all newsBrief: XOMA Royalty Announces Closing Of Tender Offer For HilleVax
Brief: Hillevax Enters Into A Definitive Agreement To Be Acquired By Xoma Royalty For $1.95 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-US energy sector, Oshkosh, Meta
U.S. STOCKS ON THE MOVE-Zumiez, BTC Digital, WesBanco
U.S. STOCKS ON THE MOVE-Petco Health, Smith & Wesson, Victoria's Secret